

Date: 10th December, 2021

To,
The Manager,
Listing Department
National Stock Exchange of India Ltd.
'Exchange Plaza' Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations, 2015")

Pursuant to Regulation 30 of the SEBI Listing Regulations, 2015, this is to inform the exchange that the Company has acquired Series Seed Preferred Stock of RIGImmune, Inc.

Please find enclosed herewith our press release.

The detailed disclosure pursuant to Regulation 30(2) of the aforesaid Regulations is also enclosed herewith as Annexure - 1.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



Charandeep Singh Saluja
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

Alembic announces seed round investment in RIGImmune, Inc.

- *RIGImmune was founded by two prominent Yale University professors*
- *Company focused on the development of novel treatments for RNA viruses*

Alembic Pharmaceuticals Limited (Alembic) has announced today that it has made a strategic investment in RIGImmune Inc., a biopharmaceutical research company co-founded by two prominent Yale University professors.

RIGImmune Inc. was founded by Dr. Anna Pyle and Dr. Akiko Iwasaki. Dr. Pyle is a Professor of Molecular, Cellular and Developmental Biology at Yale University and an investigator for the Howard Hughes Medical Institute. She is a pioneer in the field of RNA biochemistry. Dr. Akiko Iwasaki is a Professor in the Department of Immunology and a Professor of Molecular, Cellular, and Developmental Biology at Yale University. She is also an investigator for the Howard Hughes Medical Institute and a pioneer in the field of immunology. RIGImmune, Inc. is focused on the development of RNA based therapies for viral diseases and oncology applications by targeting the innate immune target, RIG-I. RIGImmune will utilize the proceeds of the series seed round to further the development of therapeutic oligonucleotides developed by Dr. Pyle and Dr. Iwasaki.

Alembic has acquired preferred stock in RIGImmune amounting to a 19.97% post-money stake in the first closing of the series seed round that was completed recently.

On this occasion, Mr. Pranav Amin, MD of Alembic stated: "We are very excited to make this investment in RIGImmune Inc., a company founded by two of the world's leading scientists in innate immunity and RNA based therapies. Alembic believes in bringing differentiated and innovative products to help address unmet needs. Apart from pursuing internal projects, we believe we can accelerate our efforts by making strategic investments in companies that are leaders in their field and this investment marks the beginning for us. We wish to thank Dr. Pyle, Dr. Iwasaki, and the management team of RIGImmune Inc. and assure them of our support in bringing these innovations to patients".


"We are delighted to have Alembic, a global pharmaceutical development firm, as a major participant in the seed financing round for RIGImmune," said Martin Driscoll, Chairman of the Board of Directors for RIGImmune. "We look forward to working with the Alembic team as we advance our novel stem loop RNA therapeutics as potential treatments for patients suffering from viral diseases and cancer".

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123



Information about Alembic can be found at <http://www.alembicpharmaceuticals.com/>;
(Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 22 - 306 11681	Phone: +91 265 - 6637630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880. • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	RIGImmune, Inc., USA Start-up entity.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	No.
3.	Industry to which the entity being acquired belongs	Research and experimental development of new chemical entities (Drug development).
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	This investment will help the Company to get into niche segment of new chemical entities.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	No.
6.	Indicative time period for completion of the acquisition	N.A.
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration.
8.	Cost of acquisition or the price at which the shares are acquired	N.A.
9.	Percentage of shareholding / control acquired and / or number of shares acquired	19.97% of Total Capital of the Target entity.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Research and experimental development of new chemical entities (Drug development) in USA. Incorporated in 2020.



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123